The clinical value of the anti-HER3 and anti-HER2 combination strategy was demonstrated in a 37-year-old woman with ER+/HER2-low breast cancer who relapsed with metastatic disease while receiving adjuvant endocrine therapy with tamoxifen (Fig 5). This evidence concerns the gene ERBB3 and breast carcinoma.